Advertisement
Singapore markets close in 3 hours 19 minutes

  • Straits Times Index

    3,173.20
    -14.46 (-0.45%)
     

  • Nikkei

    37,103.07
    -976.63 (-2.56%)
     

  • Hang Seng

    16,173.71
    -212.16 (-1.29%)
     

  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     

  • Bitcoin USD

    61,894.05
    +425.12 (+0.69%)
     

  • CMC Crypto 200

    1,283.56
    +398.02 (+43.57%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Gold

    2,398.10
    +0.10 (+0.00%)
     

  • Crude Oil

    84.70
    +1.97 (+2.38%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • FTSE Bursa Malaysia

    1,551.42
    +6.66 (+0.43%)
     

  • Jakarta Composite Index

    7,063.10
    -103.72 (-1.45%)
     

  • PSE Index

    6,421.60
    -101.59 (-1.56%)
     

GW Pharmaceuticals Focuses on Epidiolex’s US Commercial Launch

Margaret Patrick
Updated
GW Pharmaceuticals Focuses on Epidiolex’s US Commercial Launch

On September 5, the US Department of Justice and the Drug Enforcement Administration issued a press release announcing the rescheduling of Epidiolex into Schedule V of the Controlled Substances Act. According to GW Pharmaceuticals’ (GWPH) fiscal 2018 fourth-quarter earnings conference call, the company’s state government affairs team has also ensured the rescheduling of Epdiolex in Washington, D.C., as well as in the 50 US states. According to GW Pharmaceuticals’ earnings conference call, the company has been striving to reach out to 5,000 physicians about increasing the adoption of Epidiolex.

Continue reading